Home Cart Sign in  
Chemical Structure| 83280-65-3 Chemical Structure| 83280-65-3

Structure of Napabucasin
CAS No.: 83280-65-3

Chemical Structure| 83280-65-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Napabucasin (BBI608) is a STAT3 inhibitor that blocks stem cell activity in cancer cells.

Synonyms: BBI608

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Napabucasin

CAS No. :83280-65-3
Formula : C14H8O4
M.W : 240.21
SMILES Code : O=C(C1=C2OC(C(C)=O)=C1)C3=C(C2=O)C=CC=C3
Synonyms :
BBI608
MDL No. :MFCD28155270
InChI Key :DPHUWDIXHNQOSY-UHFFFAOYSA-N
Pubchem ID :10331844

Safety of Napabucasin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Napabucasin

JAK-STAT

Isoform Comparison

Biological Activity

Target
  • STAT3

In Vitro:

Cell Line
Concentration Treated Time Description References
MiaPaCa2, AsPc1, Suit2, Panc1 cells 0.5 µM, 1.0 µM, 2.0 µM 2 hours Measured STAT3 phosphorylation levels, found reduction in STAT3 phosphorylation after Napabucasin treatment Clin Cancer Res. 2019 Dec 1;25(23):7162-7174.
Murine MDSC 1 µM 24 hours Napabucasin significantly enhanced MDSC apoptosis and the expression of CD80 and MHC class II molecules, while slightly downregulating iNOS and Arg-1. J Immunother Cancer. 2022 Mar;10(3):e004384.
CT26 cells 0.1, 0.5, 1, 2, 10 µM 24 hours To evaluate the anti-tumor effect of NAP and N3-TMPs@NAP, results showed that the survival rate of cells in the N3-TMPs@NAP group decreased with increasing concentration. J Nanobiotechnology. 2023 Feb 2;21(1):37.
DLD1 and HCT116 cells 2 µM 24 hours BBI608 inhibited spherogenesis of DLD1 and HCT116 cell lines Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44.
U87MG cells 1, 5, 10 µM 24, 48, 72 hours Napabucasin significantly inhibited the proliferation of U87MG cells J Exp Clin Cancer Res. 2019 Jul 5;38(1):289.
LN229 cells 1, 5, 10 µM 24, 48, 72 hours Napabucasin significantly inhibited the proliferation of LN229 cells J Exp Clin Cancer Res. 2019 Jul 5;38(1):289.
Hepa1–6 cells 5 µM 32 hours Inhibition of IL-11-STAT3 signaling, reducing tumor cell proliferation EBioMedicine. 2019 Aug;46:119-132.
Pancreatic cancer cell lines 0.01 – 5 µM 6 hours Assessed cell viability, found differential sensitivity to Napabucasin across cell lines Clin Cancer Res. 2019 Dec 1;25(23):7162-7174.
C57BL/6 mouse primary hepatocytes 0.1 mM 72 hours To evaluate the effect of BBI608 on alcohol- and rmIL-6-induced Lcn2 mRNA expression, results showed that BBI608 pretreatment significantly suppressed Lcn2 mRNA expression. Mol Ther. 2023 Sep 6;31(9):2662-2680.
CD44high FaDu cells 400 nM 72 hours BBI608 inhibited spherogenesis of CD44high FaDu cells Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44.
Human M-MDSC 0.5 µM 96 hours Napabucasin completely abrogated the suppressive capacity of human M-MDSC on T-cell proliferation. J Immunother Cancer. 2022 Mar;10(3):e004384.
CT26 cells 0.5 µM, 1 µM To detect the protein and mRNA expression levels of CD44 and BMI1, results showed that the expression levels decreased with increasing NAP concentration. J Nanobiotechnology. 2023 Feb 2;21(1):37.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice RET transgenic melanoma mouse model Intraperitoneal injection 20 mg/kg Twice a week for 4 weeks Napabucasin significantly prolonged the survival of melanoma-bearing mice and promoted the accumulation of tumor-infiltrating antigen-presenting cells and activation of CD8+ and CD4+ T cells. J Immunother Cancer. 2022 Mar;10(3):e004384.
Mice Alcohol-induced liver metastasis model Intraperitoneal injection 20 mg/kg Every other day for 2 weeks To evaluate the preventive effect of BBI608 on alcohol-induced liver metastasis, results showed that BBI608 pretreatment significantly suppressed alcohol-induced liver metastasis. Mol Ther. 2023 Sep 6;31(9):2662-2680.
BALB/C mice CT26 colon cancer model Tail intravenous injection 20 mg/kg 14 days To evaluate the anti-tumor effect of N3-TMPs@NAP, results showed that the tumor volume and weight in the N3-TMPs@NAP group were significantly lower than those in other groups. J Nanobiotechnology. 2023 Feb 2;21(1):37.
Nude mice Pancreatic cancer xenograft model Intraperitoneal injection 20 mg/kg Daily for 14 days BBI608 significantly inhibited tumor growth in the pancreatic cancer xenograft model, and no tumor regrowth was observed during the posttreatment observation period Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):1839-44.
Nude mice Subcutaneous xenograft model of MiaPaCa2 Rosa26 or MiaPaCa2 NQO1–71 cells Oral gavage 200 mg/kg Once daily for 24 days Evaluated the effect of Napabucasin on tumor growth, found that Napabucasin significantly inhibited the growth of MiaPaCa2 Rosa26 xenografts but had no significant effect on NQO1-knockout MiaPaCa2 xenografts Clin Cancer Res. 2019 Dec 1;25(23):7162-7174.
Nude mice Orthotopic glioma model Intraperitoneal injection 40 mg/kg Every other day, until the end of the experiment Napabucasin significantly inhibited the growth of intracranial U87MG-derived tumors J Exp Clin Cancer Res. 2019 Jul 5;38(1):289.
C57BL/6 mice Hepatocellular carcinoma model Intraperitoneal injection 40 mg/kg Twice per week, for specified duration Inhibition of STAT3 phosphorylation, reducing postoperative HCC recurrence EBioMedicine. 2019 Aug;46:119-132.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01775423 Cancer, Advanced Malignancies PHASE1 COMPLETED 2015-08-06 Institute for Translational On... More >>cology Research, Greenville Hospital System, Greenville, South Carolina, 29605, United States|Ottawa Hospital Cancer Center, Ottawa, Ontario, K1H 8L6, Canada|Jewish General Hospital, Montreal, Quebec, H3T 1E2, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.16mL

0.83mL

0.42mL

20.82mL

4.16mL

2.08mL

41.63mL

8.33mL

4.16mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories